About
Peptides
Areas of Focus
Categories
Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide TherapyNJ, NY, PA
Clinical Trials (17)
View allTotal Trials
17
As Lead Sponsor
14
As Collaborator
3
Total Enrollment
1,464
By Phase
PHASE1/PHASE2: 1PHASE1: 1PHASE2: 13PHASE3: 1
By Status
COMPLETED: 8TERMINATED: 6ACTIVE_NOT_RECRUITING: 2SUSPENDED: 1
Clinical Trials Pipeline17 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05975021Lead Sponsor
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
PHASE1/PHASE2Active, not recruiting
20 participants
Started: Jun 1, 2024 · Completed: Aug 31, 2026
NCT04706962Collaborator
TH1902 in Patients With Advanced Solid Tumors
PHASE1Active, not recruiting
70 participants
Started: Mar 4, 2021 · Completed: Jan 31, 2026
NCT04389671Lead Sponsor
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
PHASE2Completed
20 participants
Started: Jan 5, 2021 · Completed: Feb 20, 2022
NCT04325035Lead Sponsor
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
PHASE2Completed
90 participants
Started: Sep 28, 2020 · Completed: Oct 30, 2024
NCT04264156Lead Sponsor
A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age
PHASE2Terminated
12 participants
Started: Apr 18, 2020 · Completed: Mar 28, 2021
Locations (1)
Headquarters
Warrington, PA, United States
Map
Loading map...